STOCK TITAN

SciSparc plans AI shift into cybersecurity and finance

The company says its AI-market evaluation may not lead to a transaction, commercial agreement or revenue-generating activity.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

SciSparc Ltd. (SPRC) announced a planned strategic shift toward Agentic AI-powered technologies, including cybersecurity and finance. The company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, following its July 27, 2026 announcement that it would target the market and its August 26, 2026 announcement establishing a Scientific Advisory Board for AI and Cybersecurity.

SciSparc describes Agentic AI as systems designed to autonomously plan and execute tasks to achieve defined objectives. It says it will continue evaluating opportunities, while cautioning that these efforts may not result in a transaction, commercial agreement or revenue-generating activity. The company also describes its existing operations through NeuroThera as clinical-stage pharmaceutical development, with drug programs based on THC and/or non-psychoactive CBD.

Filing Explained

The 6-K incorporates its October 15 press release by reference into SciSparc’s listed F-3 and S-8 registration statements from submission, unless later filings supersede it, making that disclosure part of those filings.

Agentic AI technical
"Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks"
Agentic AI refers to computer systems that can make their own decisions and take actions without needing someone to tell them what to do each time. It's like giving a robot a degree of independence to solve problems or achieve goals on its own, which matters because it could change how we work and interact with technology in everyday life.
clinical-stage medical
"engages in clinical-stage pharmaceutical developments"
Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.
THC medical
"drug development programs based on THC and/or non-psychoactive CBD"
CBD medical
"drug development programs based on THC and/or non-psychoactive CBD"
Cannabidiol (CBD) is a natural compound found in hemp and cannabis plants that does not produce the “high” associated with THC. Investors care because CBD is sold in a wide range of consumer products and medical treatments, so changes in regulation, clinical evidence, or consumer demand can quickly affect company sales, margins and legal risk — think of it as a product line whose value depends on shifting rules and public trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is SciSparc (SPRC) focusing on now?

SciSparc says it plans to shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance. It intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem.

What does Agentic AI mean in SciSparc’s announcement?

SciSparc defines Agentic AI as artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of October 2026 (Report No. 2)

 

Commission File Number: 001-38041

 

SCISPARC LTD.

(Translation of registrant’s name into English)

 

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

On October 15, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (the “Report”) and is incorporated by reference herein.

 

This Report is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release issued by SciSparc Ltd. titled “SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies.”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SCISPARC LTD.
     
  By: /s/ Oz Adler
  Name:  Oz Adler
  Title: Chief Executive Officer and Chief Financial Officer

 

Date: October 15, 2026

 

3

 

Exhibit 99.1

 

 

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

 

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.

 

Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies.

 

Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives. SciSparc aims to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector.

 

The Company will continue to evaluate opportunities in the field as it pursues its strategic shift. There can be no assurance that these efforts will result in any transaction, commercial agreement or revenue-generating activity for the Company.

 

About SciSparc Ltd. (Nasdaq: SPRC):

 

The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

 

Forward-Looking Statements:

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses its planned shift in strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies; its intention to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem; its aim to build on its scientific and technical foundation to identify opportunities in these markets and assess potential avenues for establishing its presence in the sector; and its plans to continue evaluating opportunities as it pursues its strategic shift. The Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated by its strategic shift into the field. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

 

Investor Contact:

 

IR@scisparc.com

Tel: +972-3-6167055

 

Filing Exhibits & Attachments

1 document

Keep reading